ProMIS Neurosciences Inc, a clinical─stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic...
Vous n'êtes pas connecté
CHF180000 per annum: headcount AG: Join a pioneering biotech at the forefront of neurodegenerative disease research , developing next-generation therapies for Alzheimer’s, Parkinson’s, and related disorders . Using cutting-edge technologies, this company... Lausanne
ProMIS Neurosciences Inc, a clinical─stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic...
Sensorion, a pioneering clinical─stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent...
DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene...
Rural cancer patients may miss out on cutting-edge treatments in Utah. Therapies for intellectual disorders could stall in Maryland. Red states and...
Alzheimer's disease (AD), a neurodegenerative disorder marked by amyloid plaque buildup and cognitive decline, remains a challenging condition to...
CHF120 - CHF125 per annum: headcount AG: Automation Engineer PCS7 – Programming Your chance to shape the future of PCS7 automation in a...
When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old...
Not specified: headcount AG: Brand Manager – Deutschland & Österreich (Rare Disease) Marketing mit echtem Impact – remote aus Österreich...
Not specified: headcount AG: Brand Manager – Deutschland & Österreich (Rare Disease) Marketing mit echtem Impact – remote aus Österreich...